dementia research Technology
dementia research Services
dementia research Team
dementia research Contact

What We Do:

  • StrataStem identifies, collects, and processes tissues from patients with neurological disease
  • Proprietary patient and antecedent clinical history are obtained for each patient, and they are genotyped for disease-associated variants (e.g., APOE4).
  • We derive induced pluripotent stem cells (iPSCs) from these patient tissues and differentiate them to various cell types to create in vitro disease models
  • We perform rigorous functional and geno-phenotype analyses in these disease models to define disease status/type
  • Our disease models are suitable for drug screening, target identification, target validation, toxicity screening, patient stratification, and deciphering disease mechanisms
  • Custom assays are developed for diseases based on StrataStem's knowledge and global expertise from partners in the field

iPSC Disease Models

iPSC Disease Models

To identify disease mechanisms and novel Tx targets

Companion Assays

iPSC Disease Models

To measure disease penetrance, confirm phenotype in vitro, and to validate novel Tx targets prior to therapeutics screening

Therapeutics Screening

iPSC Disease Models

We have identified novel AD therapeutics in 384-well high content screen

Why We Do It:

  • There is a huge and increasing unmet clinical need for neurological disease therapeutics
  • Many neurological diseases (e.g., Alzheimer’s, schizophrenia, epilepsy) are heterogeneous and are unlikely to be treatable by the same drug at the same time in all patients
  • Our in vitro disease models enable patient stratification for the development of targeted therapeutics and discovery of novel drug targets
  • We aim to identify interventional approaches that target disease using the right drug in the right patient at the right time
Right Drug | Right Patient | Right Time